PL3882249T3 - Pochodne deuterowane ruksolitynibu - Google Patents
Pochodne deuterowane ruksolitynibuInfo
- Publication number
- PL3882249T3 PL3882249T3 PL21156398.6T PL21156398T PL3882249T3 PL 3882249 T3 PL3882249 T3 PL 3882249T3 PL 21156398 T PL21156398 T PL 21156398T PL 3882249 T3 PL3882249 T3 PL 3882249T3
- Authority
- PL
- Poland
- Prior art keywords
- ruxolitinib
- deuterated derivatives
- deuterated
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660428P | 2012-06-15 | 2012-06-15 | |
| US201261678795P | 2012-08-02 | 2012-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3882249T3 true PL3882249T3 (pl) | 2025-09-08 |
Family
ID=48699982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21156398.6T PL3882249T3 (pl) | 2012-06-15 | 2013-06-14 | Pochodne deuterowane ruksolitynibu |
| PL18188152T PL3450434T3 (pl) | 2012-06-15 | 2013-06-14 | Deuterowane pochodne ruksolitynibu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18188152T PL3450434T3 (pl) | 2012-06-15 | 2013-06-14 | Deuterowane pochodne ruksolitynibu |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US20150197525A1 (enExample) |
| EP (4) | EP2861600A1 (enExample) |
| AU (3) | AU2013274030B2 (enExample) |
| BR (1) | BR122023027277A2 (enExample) |
| CA (1) | CA2876306C (enExample) |
| DK (2) | DK3882249T3 (enExample) |
| EA (1) | EA201492287A1 (enExample) |
| ES (2) | ES3037872T3 (enExample) |
| FI (1) | FI3882249T3 (enExample) |
| HR (1) | HRP20250965T1 (enExample) |
| HU (1) | HUE073180T2 (enExample) |
| IN (1) | IN2014DN10670A (enExample) |
| LT (1) | LT3882249T (enExample) |
| MX (2) | MX360495B (enExample) |
| PL (2) | PL3882249T3 (enExample) |
| PT (1) | PT3882249T (enExample) |
| RS (1) | RS67061B1 (enExample) |
| SI (1) | SI3882249T1 (enExample) |
| SM (1) | SMT202500302T1 (enExample) |
| WO (1) | WO2013188783A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343298B9 (en) | 2005-12-13 | 2020-05-06 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
| PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| EP2861600A1 (en) | 2012-06-15 | 2015-04-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ruxolitinib |
| TWI702057B (zh) | 2012-11-15 | 2020-08-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| RS60469B1 (sr) | 2013-08-07 | 2020-07-31 | Incyte Corp | Dozni oblici sa produženim oslobađanjem za jak1 inhibitor |
| ES2946179T3 (es) | 2014-05-28 | 2023-07-13 | Onco Tracker Inc | Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides |
| EP3325479B1 (en) | 2015-06-03 | 2020-12-02 | UWM Research Foundation, Inc. | Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use |
| DK3411031T3 (da) | 2016-02-04 | 2024-10-21 | Cindome Pharma Inc | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
| US20190048020A1 (en) * | 2016-02-12 | 2019-02-14 | Vertex Pharmaceuticals (Europe) Limited | Deuterium-modified cftr modulators |
| WO2017192905A1 (en) * | 2016-05-04 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| EP4190318A1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| WO2019104214A1 (en) | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Membrane emulsification device for microsphere creation |
| WO2019104225A1 (en) | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Therapeutic compound formulations |
| US11179412B2 (en) * | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| TW201924683A (zh) * | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| JP2021515027A (ja) | 2018-03-08 | 2021-06-17 | ノバルティス アーゲー | 抗ｐ−セレクチン抗体の使用 |
| JP7565798B2 (ja) | 2018-03-30 | 2024-10-11 | インサイト・コーポレイション | 炎症性皮膚疾患のバイオマーカー |
| EP4424328A3 (en) | 2018-03-30 | 2024-12-04 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US12325707B2 (en) | 2019-02-06 | 2025-06-10 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched JAK inhibitors |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| JP2022526301A (ja) | 2019-03-19 | 2022-05-24 | インサイト・コーポレイション | 尋常性白斑のバイオマーカー |
| WO2020210125A1 (en) | 2019-04-10 | 2020-10-15 | University Of Notre Dame Du Lac | Deuterated antimicrobial compounds |
| EP3963843A4 (en) | 2019-05-02 | 2023-01-25 | INTEL Corporation | QUALITY OF SERVICE (QOS) IN INFORMATION CENTRIC NETWORKING (ICN) |
| WO2020236950A1 (en) | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing charged polymers |
| EP4041394A1 (en) | 2019-09-16 | 2022-08-17 | Novartis AG | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| KR20220063215A (ko) | 2019-09-16 | 2022-05-17 | 노파르티스 아게 | 골수섬유증의 치료를 위한 mdm2 억제제의 용도 |
| WO2021062163A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| CN116059192B (zh) | 2019-11-13 | 2024-10-29 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| MX2022006176A (es) | 2019-11-22 | 2022-08-17 | Incyte Corp | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CA3194469A1 (en) | 2020-08-12 | 2022-02-17 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| TW202227077A (zh) | 2020-10-08 | 2022-07-16 | 瑞士商諾華公司 | Ｅｒｋ抑制劑用於治療骨髓纖維化之用途 |
| US20230390292A1 (en) | 2020-10-28 | 2023-12-07 | Sun Pharmaceutical Industries, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
| US20230404917A1 (en) * | 2020-11-19 | 2023-12-21 | Sol-Gel Technologies Ltd. | Ruxolitinib or deuterated ruxolitinib composition and uses thereof |
| PT4255442T (pt) | 2020-12-04 | 2025-05-19 | Incyte Corp | Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele |
| CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| CN114853760B (zh) * | 2021-02-03 | 2025-12-05 | 南京正大天晴制药有限公司 | 一种芦可替尼中间体的制备方法 |
| JP2024531188A (ja) | 2021-08-11 | 2024-08-29 | サン ファーマシューティカル インダストリーズ，インコーポレイテッド | 重水素化ｊａｋ阻害剤による脱毛障害の治療 |
| CA3228509A1 (en) | 2021-08-12 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| CN113820413B (zh) * | 2021-09-17 | 2023-04-07 | 重庆华邦胜凯制药有限公司 | 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法 |
| US20250275977A1 (en) | 2022-05-04 | 2025-09-04 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
| CN117384163A (zh) * | 2022-07-05 | 2024-01-12 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| WO2024196761A1 (en) * | 2023-03-17 | 2024-09-26 | Mayo Foundation For Medical Education And Research | Use of oral jak kinase inhibitors to treat lichen planus |
| CN120917022A (zh) | 2023-03-23 | 2025-11-07 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 氘代p2x3调节剂 |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
| WO2026020112A1 (en) * | 2024-07-19 | 2026-01-22 | Sun Pharmaceutical Industries, Inc. | Oral formulations of deuruxolitinib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE372966T1 (de) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| EP1390063B1 (en) | 2001-05-03 | 2004-11-17 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| EP1934201A1 (en) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| EP2343298B9 (en) | 2005-12-13 | 2020-05-06 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| MX2009002398A (es) * | 2006-09-05 | 2009-03-16 | Schering Corp | Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica. |
| RS53245B2 (sr) * | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| US7855204B2 (en) | 2008-01-22 | 2010-12-21 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2861600A1 (en) | 2012-06-15 | 2015-04-22 | Concert Pharmaceuticals Inc. | Deuterated derivatives of ruxolitinib |
| TWI702057B (zh) * | 2012-11-15 | 2020-08-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
-
2013
- 2013-06-14 EP EP13732046.1A patent/EP2861600A1/en not_active Withdrawn
- 2013-06-14 PL PL21156398.6T patent/PL3882249T3/pl unknown
- 2013-06-14 FI FIEP21156398.6T patent/FI3882249T3/fi active
- 2013-06-14 LT LTEP21156398.6T patent/LT3882249T/lt unknown
- 2013-06-14 WO PCT/US2013/045919 patent/WO2013188783A1/en not_active Ceased
- 2013-06-14 SM SM20250302T patent/SMT202500302T1/it unknown
- 2013-06-14 HR HRP20250965TT patent/HRP20250965T1/hr unknown
- 2013-06-14 PL PL18188152T patent/PL3450434T3/pl unknown
- 2013-06-14 RS RS20250758A patent/RS67061B1/sr unknown
- 2013-06-14 CA CA2876306A patent/CA2876306C/en active Active
- 2013-06-14 DK DK21156398.6T patent/DK3882249T3/da active
- 2013-06-14 EA EA201492287A patent/EA201492287A1/ru unknown
- 2013-06-14 PT PT211563986T patent/PT3882249T/pt unknown
- 2013-06-14 IN IN10670DEN2014 patent/IN2014DN10670A/en unknown
- 2013-06-14 EP EP25175288.7A patent/EP4606434A3/en active Pending
- 2013-06-14 SI SI201332107T patent/SI3882249T1/sl unknown
- 2013-06-14 BR BR122023027277-3A patent/BR122023027277A2/pt not_active Application Discontinuation
- 2013-06-14 MX MX2014015185A patent/MX360495B/es active IP Right Grant
- 2013-06-14 ES ES21156398T patent/ES3037872T3/es active Active
- 2013-06-14 EP EP18188152.5A patent/EP3450434B1/en active Active
- 2013-06-14 ES ES18188152T patent/ES2867048T3/es active Active
- 2013-06-14 AU AU2013274030A patent/AU2013274030B2/en active Active
- 2013-06-14 EP EP21156398.6A patent/EP3882249B1/en active Active
- 2013-06-14 DK DK18188152.5T patent/DK3450434T3/da active
- 2013-06-14 MX MX2018013542A patent/MX373123B/es unknown
- 2013-06-14 HU HUE21156398A patent/HUE073180T2/hu unknown
-
2014
- 2014-12-15 US US14/570,954 patent/US20150197525A1/en not_active Abandoned
-
2015
- 2015-05-08 US US14/707,912 patent/US9249149B2/en active Active
-
2016
- 2016-10-05 AU AU2016238877A patent/AU2016238877B2/en active Active
-
2017
- 2017-03-09 US US15/454,844 patent/US20170239254A1/en not_active Abandoned
-
2018
- 2018-11-26 AU AU2018271227A patent/AU2018271227B2/en active Active
-
2019
- 2019-03-11 US US16/298,795 patent/US20190308976A1/en not_active Abandoned
-
2020
- 2020-12-10 US US17/118,050 patent/US20210330674A1/en not_active Abandoned
-
2022
- 2022-12-09 US US18/078,571 patent/US20230355629A1/en active Pending
-
2024
- 2024-10-03 US US18/905,925 patent/US20250025467A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022027I2 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
| PL3882249T3 (pl) | Pochodne deuterowane ruksolitynibu | |
| SMT201700065B (it) | Derivato piridonico | |
| BR112015003153A2 (pt) | baricitinib deuterado | |
| PL2831279T3 (pl) | Szybkie wykrywanie aneuploidii | |
| LT2895484T (lt) | Gliukozilceramido sintazės inhibitoriai | |
| PL2809157T3 (pl) | Pirazolowe mieszaniny grzybobójcze | |
| AR092198A1 (es) | Derivados de pirazolopirimidinas | |
| EP2935546A4 (en) | BIORAFFINATION OF RAW TALL OIL | |
| DK2900645T3 (da) | Herbicidt aktive 3-phenylisoxazolinderivater | |
| EP2920756A4 (en) | KNOW-YOUR-CUSTOMER (KYC) EXAM | |
| FI20125510L (fi) | Laitteisto | |
| EP2858975A4 (en) | FBXO3 INHIBITORS | |
| EP2873660A4 (en) | INDOLCARBOXAMIDDERIVAT | |
| EP2813167A4 (en) | TOWEL | |
| EP2842958A4 (en) | NAPHTHOBISTHIADIAZOLDERIVAT | |
| IL259184A (en) | Crystal of flumioxazin | |
| FR2997080B1 (fr) | Inhibiteurs de neprilysine | |
| FR2987258B1 (fr) | Kit de biberons | |
| EP2918729A4 (en) | FOUNDATION | |
| UA25008S (uk) | Набір меблів | |
| TH1301004833B (th) | ขาตั้ง | |
| UA23716S (uk) | Розгортка упаковки | |
| TH1401003009B (th) | ซัพพอร์ตเตอร์ | |
| UA24624S (uk) | Набір упаковок |